Profile
Edward L.
Field served as President & CEO of Inologic, Inc. from 2004-2004.
He was the Chief Business Officer & Executive Vice President of Aldagen, Inc. from 2010-2012.
He was also the Chief Operating Officer of Nuo Therapeutics, Inc. from 2012-2014.
In addition, he served as President of Molecumetics Ltd.
from 2002-2002.
From 2015-2017, he was the President-DISC Division of BioRestorative Therapies, Inc. Mr. Field received his undergraduate degree from Duke University and his MBA from the University of Virginia Darden School of Business.
Former positions of Edward L. Field
| Companies | Position | End |
|---|---|---|
| BIORESTORATIVE THERAPIES, INC. | Corporate Officer/Principal | 2017-07-23 |
| NUO THERAPEUTICS, INC. | Chief Operating Officer | 2014-06-29 |
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | President | 2010-02-23 |
| Inologic, Inc. | President | 2004-08-31 |
| Molecumetics Ltd. | President | 2001-12-31 |
Training of Edward L. Field
| Duke University | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NUO THERAPEUTICS, INC. | Health Technology |
| BIORESTORATIVE THERAPIES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
| Inologic, Inc. | |
| Molecumetics Ltd. |
- Stock Market
- Insiders
- Edward L. Field
